Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AOH1996 |
Synonyms | |
Therapy Description |
AOH1996 targets PCNA and increases interaction with POLR2A, resulting in increased POLR2A degradation, and potentially leading to decreased DNA repair, increased replication stress and tumor cell apoptosis, and reduced tumor growth (PMID: 37531956). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AOH1996 | AOH 1996|AOH-1996 | AOH1996 targets PCNA and increases interaction with POLR2A, resulting in increased POLR2A degradation, and potentially leading to decreased DNA repair, increased replication stress and tumor cell apoptosis, and reduced tumor growth (PMID: 37531956). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06763341 | Phase I | AOH1996 + Azacitidine + Venetoclax AOH1996 + Venetoclax AOH1996 | AOH1996 Alone or in Combination With Venetoclax With or Without Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT05227326 | Phase I | AOH1996 | AOH1996 for the Treatment of Refractory Solid Tumors | Recruiting | USA | 0 |